Ginkgo Bioworks Holdings Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Three Months Ended September 30, 2024 | ||||||
|---|---|---|---|---|---|---|
| Common Stock | ||||||
| Shares | Amount | AdditionalPaid-InCapital | Accumulated Deficit | AccumulatedOtherComprehensiveIncome (Loss) | TotalStockholders’Equity | |
| Balance as of June 30, 2024 | 51,970 | $5 | $6,508,410 | $(5,673,620) | $(1,723) | $833,072 |
| Issuance of common stock upon exercise or vesting of equity awards | 422 | — | — | — | — | — |
| Settlement of contingent consideration | 690 | — | 5,437 | — | — | 5,437 |
| Payment for fractional shares after reverse stock split | — | — | (4) | — | — | (4) |
| Stock-based compensation expense | — | — | 13,855 | — | — | 13,855 |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | — | — | — | — | 1,492 | 1,492 |
| Foreign currency translation | — | — | — | — | 494 | 494 |
| Net loss | — | — | — | (56,403) | — | (56,403) |
| Balance as of September 30, 2024 | 53,082 | $5 | $6,527,698 | $(5,730,023) | $263 | $797,943 |
| Nine Months Ended September 30, 2024 | ||||||
| Common Stock | ||||||
| Shares | Amount | AdditionalPaid-InCapital | Accumulated Deficit | AccumulatedOtherComprehensiveIncome (Loss) | TotalStockholders’Equity | |
| Balance as of December 31, 2023 | 50,034 | $5 | $6,386,191 | $(5,290,528) | $1,484 | $1,097,152 |
| Issuance of common stock upon exercise or vesting of equity awards | 1,414 | — | 543 | — | — | 543 |
| Payment for fractional shares after reverse stock split | — | — | (4) | — | — | (4) |
| Settlement of contingent consideration | 764 | — | 9,884 | — | — | 9,884 |
| Issuance of common stock for asset acquisitions | 802 | — | 36,801 | — | — | 36,801 |
| Issuance of common stock in exchange for services | 68 | — | 2,500 | — | — | 2,500 |
| Stock-based compensation expense | — | — | 91,783 | — | — | 91,783 |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | — | — | — | — | 1,492 | 1,492 |
| Foreign currency translation | — | — | — | — | (2,713) | (2,713) |
| Net loss | — | — | — | (439,495) | — | (439,495) |
| Balance as of September 30, 2024 | 53,082 | $5 | $6,527,698 | $(5,730,023) | $263 | $797,943 |
Condensed Consolidated Statements of Stockholders’ Equity
| Three Months Ended September 30, 2023 | ||||||
|---|---|---|---|---|---|---|
| Common Stock | ||||||
| Shares | Amount | AdditionalPaid-InCapital | Accumulated Deficit | AccumulatedOtherComprehensiveLoss | TotalStockholders’Equity | |
| Balance as of June 30, 2023 | 48,869 | $5 | $6,280,823 | $(4,775,943) | $(1,300) | $1,503,585 |
| Issuance of common stock upon exercise or vesting of equity awards | 440 | — | 55 | — | — | 55 |
| Settlement of contingent consideration | 11 | — | 960 | — | — | 960 |
| Stock-based compensation expense | — | — | 52,573 | — | — | 52,573 |
| Foreign currency translation | — | — | — | — | (1,599) | (1,599) |
| Net loss | — | — | — | (302,891) | — | (302,891) |
| Balance as of September 30, 2023 | 49,320 | $5 | $6,334,411 | $(5,078,834) | $(2,899) | $1,252,683 |
| Nine Months Ended September 30, 2023 | ||||||
| Common Stock | ||||||
| Shares | Amount | AdditionalPaid-InCapital | Accumulated Deficit | AccumulatedOtherComprehensiveLoss | TotalStockholders’Equity | |
| Balance as of December 31, 2022 | 47,300 | $5 | $6,136,563 | $(4,397,659) | $(2,632) | $1,736,277 |
| Issuance of common stock upon exercise or vesting of equity awards | 1,888 | — | 539 | — | — | 539 |
| Tax withholdings related to net share settlement of equity awards | — | — | (23) | — | — | (23) |
| Settlement of contingent consideration | 11 | — | 3,222 | — | — | 3,222 |
| Issuance of common stock for asset acquisitions | 70 | — | 3,581 | — | — | 3,581 |
| Issuance of common stock in exchange for services | 51 | — | 2,500 | — | — | 2,500 |
| Stock-based compensation expense and other | — | — | 188,029 | — | — | 188,029 |
| Foreign currency translation | — | — | — | — | (267) | (267) |
| Net loss | — | — | — | (681,175) | — | (681,175) |
| Balance as of September 30, 2023 | 49,320 | $5 | $6,334,411 | $(5,078,834) | $(2,899) | $1,252,683 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.